公开(公告)号：US12275795B2

公开(公告)日：2025-04-15

申请号：US17934064

申请日：2022-09-21

Applicant: NOVARTIS AG

Inventor： Aida Abujoub ,  John Blankenship ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Haihui Lu

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C07K16/46 ,  C12N5/10 ,  C12N15/63 ,  A61K39/00

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US11952428B2

公开(公告)日：2024-04-09

申请号：US18170941

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20230416390A1

公开(公告)日：2023-12-28

申请号：US18184860

申请日：2023-03-16

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20240189439A1

公开(公告)日：2024-06-13

申请号：US18454457

申请日：2023-08-23

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC: A61K47/68 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US11939389B2

公开(公告)日：2024-03-26

申请号：US18170969

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20230183368A1

公开(公告)日：2023-06-15

申请号：US18170969

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US11608382B2

公开(公告)日：2023-03-21

申请号：US16439495

申请日：2019-06-12

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20240299574A1

公开(公告)日：2024-09-12

申请号：US18672871

申请日：2024-05-23

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph A. D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles

IPC: A61K47/68 ,  A61K31/4745 ,  A61K45/06 ,  A61P35/00 ,  C07K16/18

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20220396631A1

公开(公告)日：2022-12-15

申请号：US17595637

申请日：2020-05-19

Applicant: Lu HUANG ,  Brian GRANDA ,  John BLANKENSHIP ,  Aida ABUJOUB ,  Tony FLEMING ,  Haihui LU ,  Connie HONG ,  Brian HOLMBERG ,  Novartis AG

Inventor： Brian Walter Granda ,  John Blankenship ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  Brian Holmberg ,  Haihui Lu

IPC: C07K16/28

Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.

公开(公告)号：US20220364055A1

公开(公告)日：2022-11-17

申请号：US17271430

申请日：2019-08-30

Applicant: Novartis AG

Inventor： Louise Treanor ,  Michael R. Greene ,  Jennifer Brogdon ,  Boris Engels ,  Glenn Dranoff ,  Olja Kodrasi ,  Hyungwook Lim ,  Akash Sohoni ,  Elizabeth Dorothy Pratico ,  Anniesha Hack ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  John Blankenship ,  Brian Holmberg ,  Chonghui Zhang ,  Dexiu Bu ,  Andrew Price ,  Xu Zhu ,  Andrew Stein ,  Attilio Bondanza

IPC: C12N5/0783 ,  A61K35/17 ,  A61K31/519 ,  A61K38/20 ,  C07K16/28 ,  C07K14/705

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.